Non-carbohydrate anaplerotic therapy counters empagliflozin-induced diabetic ketosis.

ABSTRACT:

Background

SGLT2 inhibitors (SGLTi) confer significant cardiometabolic benefits in diabetes, but are associated with increased risk of diabetic ketoacidosis (DKA). We hypothesized that supporting anaplerosis with glycerol could mitigate SGLTi-induced ketosis, enhance insulin-mediated resolution of severe diabetic ketosis, and lower the risk of DKA when used as a dietary supplement.

Methods

Insulin-dependent diabetes was induced in yearling sheep using alloxan. The animals subsequently developed severe hyperglycemia (glucose > 500 mg/dL) and hyperketonemia (β-hydroxybutyrate [BHB] > 5 mM), requiring daily insulin therapy for metabolic control and survival. Ketosis was induced by partial insulin withdrawal and with the administration of 10 mg of the SGLT2 inhibitor empaglifloz

SUBMITTER: Asiku J 

PROVIDER: S-EPMC12559390 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature